Search Results

Lucira Health, Inc. announced the launch of Lucira Connect, a new virtual care program that allows Lucira test users the ability to test, learn about treatment options, access a telehealth consultation, and if appropriate, receive a prescription all from home for only the $29 price of the test, excluding prescription costs.

Lucira Health, Inc. announced the Canadian launch of Lucira Connect, a new virtual care program that allows Lucira test users the ability to test, learn about treatment options, access a telehealth consultation, and if appropriate, receive a prescription all from home for only the price of the test, excluding prescription costs.

Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients with providers, today announced that the company will report third quarter 2022 financial results on, Monday, November 14th, 2022.

A recruiter and career coach discuss when and why some biotech and pharma professionals put a premium on health insurance benefits.

Acceptance of TempraMed’s products by Meuhedet Health Services strengthens TempraMed’s B2B institutional commercialization strategy as the Company advances reimbursement initiatives and expands relationships with leading healthcare organizations globally Highlights Meuhedet Health Services, Israel’s third-largest Health Maintenance Organization (HMO), serving more than one million insured members, has accepted TempraMed’s flagship VIVI Cap™ and VIVI Epi™ products. TempraMed products are now accepted by two of Israel’s four national HMOs—Maccabi Healthcare Services and Meuhedet—providing institutional access to approximately four million insured lives. The Company is executing a global B2B institutional strategy focused on healthcare organizations, insurers, distributors and government healthcare systems.

Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report second quarter 2022 financial results on, Monday, August 15, 2022.

Lucira Health, Inc. (“Lucira Health” or “Lucira”) (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of innovative infectious disease tests today announced that on July 27, 2022, the Board of Directors of Lucira granted inducement awards consisting of 1,051,405 restricted stock units (“RSUs”) under Lucira’s 2022 Inducement Plan.